These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 22387451)
1. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Coleman RL; Broaddus RR; Bodurka DC; Wolf JK; Burke TW; Kavanagh JJ; Levenback CF; Gershenson DM Gynecol Oncol; 2006 Apr; 101(1):126-31. PubMed ID: 16271384 [TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Matei D; Emerson RE; Schilder J; Menning N; Baldridge LA; Johnson CS; Breen T; McClean J; Stephens D; Whalen C; Sutton G Cancer; 2008 Aug; 113(4):723-32. PubMed ID: 18618737 [TBL] [Abstract][Full Text] [Related]
4. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers. Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942 [TBL] [Abstract][Full Text] [Related]
5. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Berkenblit A; Seiden MV; Matulonis UA; Penson RT; Krasner CN; Roche M; Mezzetti L; Atkinson T; Cannistra SA Gynecol Oncol; 2004 Dec; 95(3):624-31. PubMed ID: 15581974 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063 [TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Sabbatini P; Aghajanian C; Dizon D; Anderson S; Dupont J; Brown JV; Peters WA; Jacobs A; Mehdi A; Rivkin S; Eisenfeld AJ; Spriggs D J Clin Oncol; 2004 Nov; 22(22):4523-31. PubMed ID: 15542803 [TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157 [TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896 [TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848 [TBL] [Abstract][Full Text] [Related]
13. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330 [TBL] [Abstract][Full Text] [Related]
15. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study. Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118 [TBL] [Abstract][Full Text] [Related]
16. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839 [TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5). Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545 [TBL] [Abstract][Full Text] [Related]
19. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Friedlander M; Hancock KC; Rischin D; Messing MJ; Stringer CA; Matthys GM; Ma B; Hodge JP; Lager JJ Gynecol Oncol; 2010 Oct; 119(1):32-7. PubMed ID: 20584542 [TBL] [Abstract][Full Text] [Related]
20. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Modi S; Seidman AD; Dickler M; Moasser M; D'Andrea G; Moynahan ME; Menell J; Panageas KS; Tan LK; Norton L; Hudis CA Breast Cancer Res Treat; 2005 Mar; 90(2):157-63. PubMed ID: 15803362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]